“Spark”, the project led by Iproteos to combat schizophrenia

“La Vanguardia”, together with other national and international media outlets, has published a news story about “Spark”, a project launched by a public-private consortium led by Iproteos, an IRB Barcelona and UB spin-off located at PCB. IRB Barcelona, CRG, the University of the Bask Country, and the biopharmaceutical company Ascil-Biopharma are also involved in the project.

The aim of Spark is to carry out the first preclinical stage of the development of a first-in-class drug to prevent, stop and reverse the progression of cognitive impairment associated with schizophrenia.